Randomization and blinding
BLIND
Eligible participants within each age category were randomly assigned in a 2:1 ratio to receive either NmCV-5 (n=400) or MenACWY-D (n=200). Randomization was undertaken using a web-based system, according to a permuted block randomization scheme. Randomization, vaccine preparation and administration were undertaken by unblind personnel who were not involved in other participant-related procedures or endpoint collection. Parents, participants, and all other trial staff were blind to treatment allocation.